[{"id":"a6e18105-9457-47d7-93da-0d2d96852d1c","acronym":"HCRN LUN21-497","url":"https://clinicaltrials.gov/study/NCT05617313","created_at":"2022-11-15T15:57:34.931Z","updated_at":"2025-02-25T16:18:18.717Z","phase":"Phase 2","brief_title":"Study of GT103 in Combination With Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05617313 - HCRN LUN21-497","lead_sponsor":"Jeffrey Clarke","biomarkers":" EGFR • KRAS • BRAF • ALK • MET • ROS1","pipe":" | ","alterations":" KRAS G12C • MET exon 14 mutation • KRAS G12","tags":["EGFR • KRAS • BRAF • ALK • MET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS G12C • MET exon 14 mutation • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • GT103"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 21","initiation":"Initiation: 02/17/2023","start_date":" 02/17/2023","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2028","study_completion_date":" 01/01/2028","last_update_posted":"2024-07-19"},{"id":"cc21565b-18bb-4757-8beb-6eeeba3a1b20","acronym":"","url":"https://clinicaltrials.gov/study/NCT04314089","created_at":"2021-01-18T20:54:37.113Z","updated_at":"2024-07-02T16:35:22.839Z","phase":"Phase 1","brief_title":"Phase Ib First in Human Dose Escalation of GT103 in Refractory, Advanced Stage Non-Small Cell Lung Cancer (TOP 1902)","source_id_and_acronym":"NCT04314089","lead_sponsor":"Edward Patz","biomarkers":" EGFR • ALK • ROS1","pipe":"","alterations":" ","tags":["EGFR • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GT103"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 06/09/2020","start_date":" 06/09/2020","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-01-19"}]